We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Levels of suPAR Protein Predict Risk of Blood Clot Formation in Covid-19 Patients

By LabMedica International staff writers
Posted on 05 Aug 2022
Print article
Image: Three-dimensional rendered illustration of a blood clot (Photo courtesy of 123rf.com)
Image: Three-dimensional rendered illustration of a blood clot (Photo courtesy of 123rf.com)

Elevated levels of soluble urokinase plasminogen activator receptor are indicative of the risk of blood clot formation in Covid-19 patients.

The urokinase plasminogen activator (uPA)/urokinase plasminogen activator receptor (uPAR) system is abundant in various cell types, including vascular endothelial cells, and is known as a key regulator in the cross‐reactions between vascular inflammation, immunity, and coagulopathy (impairment in the blood’s ability to clot). The soluble uPAR (suPAR) is a cleavage product from the uPA/uPAR system, levels of which are thought to reflect the system's overall activity. suPAR levels are three- to five‐fold higher in patients with COVID‐19, elevated earlier than other biomarkers in disease progression, and strongly associated with COVID‐19 complications, including death, respiratory failure requiring mechanical ventilation, and severe acute kidney injury. Thus, suPAR may be an ideal biomarker to quantify potential for blood clot formation in COVID‐19.

To test this hypothesis, investigators at the University of Michigan (Ann Arbor, USA) measured D-dimer (a small protein fragment present in the blood after a blood clot has been degraded by fibrinolysis, which is measured in people with suspected thrombotic disorders) and suPAR levels from 1960 patients over a 30-day period during patients' hospitalizations. VTE (deep vein thrombosis and pulmonary embolism) was diagnosed using ultrasounds of the lower extremities and scans of the lungs.

Results revealed that VTE occurred in 163 patients, and of those, 65 patients developed deep vein thrombosis, 88 patients developed a pulmonary embolism, and 10 patients developed both. Patients who developed blood clots had suPAR levels nearly 50% higher than those who did not develop clots. In addition, when suPAR levels were combined with D-dimer, it was possible to classify 41% of study participants as having low-risk for occurrence of VTE.

Senior author Dr. Salim S. Hayek, assistant professor of internal and cardiovascular medicine at the University of Michigan, said, "Even before the pandemic, before COVID-19, we had this idea about suPAR. We were seeing levels of the suPAR marker as the strongest risk factor for bad outcomes in other viral infections and in heart and kidney disease. We had previously shown that patients with high suPAR levels are at much higher risk of death, kidney injury, respiratory failure needing mechanical ventilation, and now venous thromboembolism. In the background, there has been a lot of work showing that this molecule (suPAR) is doing something bad to the body when levels are high. Companies are developing drugs to target suPAR, and so we might be measuring this on a regular basis."

The suPAR study was published in the August 4, 2022, online edition of the Journal of the American Heart Association.

Related Links:
University of Michigan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.